Startsida4530 âą TYO
add
Hisamitsu Pharmaceutical Co Inc
FöregÄende stÀngning
6 037,00 „
Dygnsintervall
6 037,00 „ - 6 045,00 „
Ă
rsintervall
3 783,00 „ - 6 695,00 „
BörsvÀrde
453,92Â md JPY
Genomsnittlig volym
620,79Â tn
P/E-tal
21,80
Direktavkastning
-
PrimÀr börs
TYO
Aktuellt
Ekonomi
ResultatrÀkning
IntÀkter
Nettoinkomst
| (JPY) | nov. 2025info | FörÀndring Y/Y |
|---|---|---|
IntÀkter | 39,57 md | 10,54 % |
Rörliga kostnader | 18,66 md | 5,05 % |
Nettoinkomst | 4,87Â md | 6,71Â % |
Nettovinstmarginal | â | â |
Vinst per aktie | â | â |
EBITDA | 6,06Â md | â |
Giltig skattesats | â | â |
BalansrÀkning
Totala tillgÄngar
Totala ansvarsskyldigheter
| (JPY) | nov. 2025info | FörÀndring Y/Y |
|---|---|---|
Kontanta och kortsiktiga investeringar | 110,78Â md | â5,03Â % |
Totala tillgÄngar | 342,31 md | 2,24 % |
Totala ansvarsskyldigheter | 70,70Â md | â2,50Â % |
Totala tillgĂ„ngar | 271,61 md | â |
UtestĂ„ende aktier | 70,07 mn | â |
P/B | 1,57 | â |
Avkastning pĂ„ tillgĂ„ngar | â | â |
Avkastning pĂ„ kapital | â | â |
Kassaflöde
FörÀndring i nettokassa
| (JPY) | nov. 2025info | FörÀndring Y/Y |
|---|---|---|
Nettoinkomst | 4,87Â md | 6,71Â % |
Kontanter frĂ„n verksamhet | â | â |
Kontanter frĂ„n investering | â | â |
Kontanter frĂ„n finansiering | â | â |
FörĂ€ndring i nettokassa | â | â |
Fritt kassaflöde | â | â |
Om
The Hisamitsu Pharmaceutical Co., Inc., headquartered in Tosu and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology since the introduction of its original line of patches in 1903.
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration. Wikipedia
Grundades
1847
Huvudkontor
Hemsida
AnstÀllda
2Â 799